Optimisation of MTX treatment in rheumatoid arthritis:: Current reflections on a personalised approach

This thesis focused on steps towards Therapeutic Drug Monitoring (TDM) for effective MTX treatment and methods to measure(non)adherence towards MTX and biological DMARDs. We studied pharmacokinetics and –dynamics of red blood cell (RBC)-MTX-PGs, ways to personalise MTX treatment, including a comparison of different cell types in which MTX was measured, and a proposed PKPD model. As a bridge, drug levels of MTX were compared with electronic monitoring of drug intake. Furthermore, adherence to (biological) DMARDs and ways to measure and improve this were revealed. For more information, please see the full summary.